TNFRSF1B and Alzheimer disease: AD mice were treated thrice-weekly for 12 weeks by intra-peritoneal (IP) injection of 3 mg/kg of the TfRMAb-TNFR2 fusion protein, and this treatment caused a reduction in brain amyloid plaque, a decrease in brain immunoreactive intercellular adhesion molecule 1 (ICAM1), a marker of neuroinflammation, and an increase in recognition memory in the AD mice [125].